Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kosuke Horita"'
Autor:
Motomu Nakatake, Hajime Kurosaki, Nozomi Kuwano, Kosuke Horita, Mai Ito, Hiromichi Kono, Tomotaka Okamura, Kosei Hasegawa, Yasuhiro Yasutomi, Takafumi Nakamura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 14, Iss , Pp 159-171 (2019)
Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables it
Externí odkaz:
https://doaj.org/article/62edb807eaa94f1ca4186d396229d2e9
Autor:
Kosuke Horita, Hajime Kurosaki, Motomu Nakatake, Nozomi Kuwano, Tetsuro Oishi, Hiroaki Itamochi, Sho Sato, Hiromichi Kono, Mai Ito, Kosei Hasegawa, Tasuku Harada, Takafumi Nakamura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 13, Iss , Pp 35-48 (2019)
Oncolytic vaccinia virus (OVV) has demonstrated appropriate safety profiles for clinical development. Although designed to kill cancer cells efficiently, OVV sensitivity varies in individual cancers, and predictive biomarkers of therapeutic responses
Externí odkaz:
https://doaj.org/article/54a365e194da4d77a77a032f2fc828f0
Publikováno v:
Biochemical and Biophysical Research Communications. 516:831-838
The promising anti-tumor effects of oncolytic vaccinia virus (OVV) have been demonstrated. Further, we previously showed that long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) enhances OVV cell-to-cell spread via the activation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad1284ac16dde27f8aec6813b52e4be
https://doi.org/10.1016/j.bbrc.2019.06.125
https://doi.org/10.1016/j.bbrc.2019.06.125
Autor:
Kosei Hasegawa, Hiromichi Kono, Hajime Kurosaki, Kosuke Horita, Motomu Nakatake, Sho Sato, Takafumi Nakamura, Tetsuro Oishi, Tasuku Harada, Hiroaki Itamochi, Nozomi Kuwano, Mai Ito
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 13, Iss, Pp 35-48 (2019)
Molecular Therapy: Oncolytics, Vol 13, Iss, Pp 35-48 (2019)
Oncolytic vaccinia virus (OVV) has demonstrated appropriate safety profiles for clinical development. Although designed to kill cancer cells efficiently, OVV sensitivity varies in individual cancers, and predictive biomarkers of therapeutic responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f56208a7832e4121391c89d3e90db21e
https://doi.org/10.1016/j.omto.2019.03.003
https://doi.org/10.1016/j.omto.2019.03.003
Autor:
Tomotaka Okamura, Hiromichi Kono, Mai Ito, Kosei Hasegawa, Nozomi Kuwano, Yasuhiro Yasutomi, Hajime Kurosaki, Motomu Nakatake, Takafumi Nakamura, Kosuke Horita
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 14, Iss, Pp 159-171 (2019)
Molecular Therapy: Oncolytics, Vol 14, Iss, Pp 159-171 (2019)
Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfaf790c2d324b453ecfacc735c7aa92
https://pubmed.ncbi.nlm.nih.gov/31236440
https://pubmed.ncbi.nlm.nih.gov/31236440